~" The development of monoclonal antibodies has resulted in marked expansion in understanding the central nervous system (CNS). This has been especially true in the study of human neuroectodermal tumors where monoclonal antibodies have been used as physiological probes to define and characterize human neuroectodermal tumor-associated antigens. Utilizing monoclonal antibodies, neuroectodermal tumor-associated antigens have been described in four broad categories; biochemically defined markers, shared nervous systemlymphoid cell markers, shared neuroectodermal-oncofetal markers, and putative restricted tumor markers. Preliminary data have demonstrated the ability to localize animal and human tumors in vitro, ex vivo, and in vivo. Early application of monoclonal antibody technology to neuroimmunology and neuro-oncology has resulted in a new awareness of the complex relationships that exist within the CNS. Their specificity and reproducibility may provide the means to qualitatively and quantitatively define the phenotypic heterogeneity of human neuroectodermal tumors. Potentially, monoclonal antibodies, alone or as carriers of radionuclides, drugs, or toxins, may allow successful diagnosis and treatment of human neuroectodermal tumors.
I
N much the same way that computerized tomography has influenced the clinical neurosciences, hybridoma technology has influenced the basic neurosciences. Nowhere should this technology be felt more than in neuro-oncology because of the enormous potential, as yet unrealized clinically, for monoclonal antibodies to increase specificity in diagnosis and treatment of central nervous system (CNS) tumors. The development of monoclonal antibodies for the study of human neuroectodermal tumors has resulted in a new appreciation of the complexity of the cellular components of the CNS and a dawning comprehension of the relationships between normal and neoplastic cells. To begin to understand how this has come about, an introduction to the interrelated areas of neurooncology and neuroimmunology is needed.
This contribution is the 17th in a series of review articles selected jointly by the Committee on Graduate Education of the American Association of Neurological Surgeons and the Congress of Neurological Surgeons, and the Journal of Neurosurgery. --Editor.
Neuro-oncology and Neuroimmunology

Tumor-Associated Antigens
It is estimated that cancer accounts for more than 19% of the cumulative yearly mortality in the United States, ranking as the second leading cause of death. 47 ' 169 Among the most devastating of the cancers are those neuroectodermal tumors that involve the CNS. The patients' age at onset and the poor prognosis make the economic and personal impact of these tumors far greater than numbers alone would indicate, ranking fourth among males and eighth among females in the order of neoplastic causes for lost work years. 126 Malignant gliomas, which are the most commonly occurring primary CNS tumors in adults (representing between 15% and 40% of all intracranial neoplasms) and medulloblastomas (which account for one-fourth of all pediatric brain tumors) 27,61,166 are, in large part, responsible for this situation. 27'1' 87"165 ' 185 Treatment of these tumors with surgical resection and external radiotherapy has reached a plateau, since further extension would Monoclonal antibodies and primary brain tumor lead to unacceptable side effects, including neurological deficits, radiation necrosis of the brain, 26 and delayed reduction in mental status. 85 Unfortunately, current adjuvant chemotherapy has met with only marginal success. 27"51' 165 While many factors are involved in this poor response to therapy, cumulative evidence strongly suggests that their biological heterogeneity, including variation in blood-brain barrier permeability which may limit access of drugs, is a major factor. 6-9'24"z5"182 Because the majority of work done in neuro-oncology and neuroimmunology utilizing monoclonal antibodies has focused on malignant gliomas, this review will largely deal with that topic. Much of the data and techniques discussed, however, are directly pertinent to the other primary CNS tumors, most notably the medulloblastomas. Morphologically, the diversity of the cellular components of malignant gliomas was first described by Virchow in 1865183 and has been confirmed by all subsequent authorsfl 7'152 Phenotypically, cultured glioma cells also have a high degree of variability, including morphology, growth kinetics, expression of biochemical markers, tumorigenicity in nude mice, response to chemotherapeutic agents, and antigen expression. 6-9'24'25 Newer techniques have shown that this biological variability may have a genotypic basis, since, both within and among individuals, gliomas have variances in modal chromosome number, marker chromosomes, and DNA (deoxyribonucleic acid) content. 6'7"1~ Recognition of this heterogeneity and of the limitations of current therapy has focused renewed interest on attempts to individualize glioma therapy.
Scientists and clinicians have long been intrigued with the idea that human tumors might express specific tumor antigens on their cell surface. There is increasing evidence that this may be true of human brain tumors, most specifically malignant glial tumors. Human and experimental brain tumors have been demonstrated to have glioma-associated antigens. 6' 18' 34-39 ' 112"113"158"186' ~88-191 Beginning in 1965, Mahaley and Day and their colleagues41,42.112.113 reported their experience with a rabbit-antiglioma serum which could, following extensive absorption, preferentially localize in human glioma tissue after intra-arterial administation (Fig. 1) . In later studies, Coakham and Lakshmi 38'39 described a rabbitantiglioma serum against astrocytoma-associated antigens, although this serum was not shown to be definitely species-nonreactive. Subsequently, Miyake, et al., 121 and Sato, et al., ~53 produced rabbit sera against human glioma cells, although in neither study was adequate absorption with normal brain performed, and neither serum was truly usable as a glial tumor-specific probe.
In no instance has a specific response to a common tumor-associated antigen been well defined and documented in polyclonal serological analysisJ 86,187 From recent data using monoclonal antibodies, this failure may be largely explained by the limitations associated with the use of polyclonal antibodies.
FIG. 1. Schematic drawing of an antibody. This demonstrates the basic structure including light and heavy chains and the constant and variable regions. Antigen-binding occurs in the variable region while such biologically mediated events as complement activation and monocyte binding occur at the Fc portion of the constant region. When an antibody is digested by the enzyme papain, two Fab fragments and one Fc fragment are derived. The Fab fragments are capable of binding to antigens without the induction of such processes as complement activation. In contrast, digestion with pepsin results in destruction of the Fc portion of the antibody, while the two Fab fragments are still attached at a disulfide bond producing the F(ab')2 fragment.
Monoclonal Versus Polyclonal Antibodies
When an organism is exposed to an immunogenic substance, a very heterogeneous reaction occurs. When a single antigenic determinant is used for immunization, this heterogeneity is in the variable affinities of the multiple groups of antibodies that arise against the single determinant (Fig. 2) . If this is a substance which has multiple antigenic determinants, as most immunogens do, then the heterogeneity is a function of both antibody specificity to the different antigenic determinants and the variable antibody-binding affinities to each antigen site. There are several ways that this heterogeneous response can be made more uniform. One of these is serial immunization. With serial immunization, the average affinity of the antibody pool tends to increase, resulting in a maturation of the immune response. However, the serum produced by this technique is still quite heterogeneous, with serial and specific absorption required to reduce antibody variability in the serum. This generally results in the recovery of low amounts of antibody, and many animals are needed to obtain large amounts of reagent. A major breakthrough in this area occurred with the development of hybridoma technology and the subsequent production of monoclonal antibodies. 95 Hybridomas are cells that have been formed by the artificial fusion of genetic material from two different cell lines. Although human-human and human-primate fusions are possible and will be discussed later, the vast majority of hybridoma cell lines are derived from murine cells. A murine myeloma cell line, which has the genetic information for indefinite proliferation in tissue culture, is fused using either polyethylene glycol or Sendai virus with B lymphocytes from an animal immunized against a specific antigen. The B lymphocytes, having been exposed to the selected immunogen, possess the genetic information for producing the desired antibody, but not for neoplastic proliferation. To insure that only the hybrid cells grow, the fusion medium is prepared lacking the substrate that the parent myeloma cell line (but not the normal lymphocytes) requires for growth. Thus, only hybrid cells with genetic information from both parent lines can proliferate. Following fusion, the cells are suspended in medium, separated into single cell chambers, and allowed to grow. The supernatant from the multitude of cells produced is carefully screened for the presence of the desired antibody. Since the eventual hybridoma cell line is derived
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from a single antibody-producing cell, the population of antibodies produced by any given hybridoma is uniform and directed against a single antigenic determinant. Because of these features of homogeneity and continuous production, hybridoma technology can provide enormous quantities of a single immunoglobulin. This methodology, although still in an early stage of development, has already had tremendous impact upon immunology and medicine, allowing a specificity and reproducibility previously not possible with polyclonal antibodies.
In addition to the uniformity and the ease of producing large amounts of antibody, monoclonal antibodies have other theoretical advantages. These center around the increased potential for use in vivo, and are based upon the great degree of specificity. Also, there is an advantage in using radiolabeled monoclonal antibodies for in vivo imaging, because of the ease of using indifferent monoclonal antibodies of the same class to subtract background interaction, and their potential ability to use lesser amounts of radiolabeling material because of purity. Already monoclonal antibodies have been developed against a wide spectrum of antigens, including human neuroectodermal tumor-associated antigens, normal CNS-associated antigens, extracellular matrix proteins, and biochemically defined markers.16,17,37,46,54.71, [115] [116] [117] [158] [159] [160] 186, 189, 190 Despite these obvious advantages of monoclonal antibodies, their true value is still being defined. While much more specific than polyclonal antibodies, they are not necessarily more sensitive. 16,115,116 Moreover, the heterogeneity of malignant gliomas has been used to suggest that a single monoclonal antibody may not allow wide cross-reactivity. These limitations can be overcome by the use of panels of monoclonal antibodies, which are more sensitive than a single one, and would potentially allow tissues to be better characterized.16'71 The majority of hybridomas currently utilized are of murine derivation and have several theoretical and practical limitations. Murine monoclonal antibodies have been unable to detect certain human major histocompatibility complex (HLA) specificities readily detectable by human polyclonal antibody sera, suggesting a possible reduced interspecies response. 85 Also, the use of routine monoclonal antibodies does not allow reproduction of the unique autochthonous human immunological responses that have been reported to occur in draining lymph nodes or with intratumorous lymphocytes. 52 ' 134"136, 137, 147"165"168 Finally, there is the potential for interspecies reaction if murine monoclonal antibodies are used in humans. To circumvent these problems, initial work has been done in the attempted production of human-human and human-primate monoclonal antibodies, s8 ' 131' 132"138' 168 Early experiments were largely unsuccessful due to the failure to demonstrate a true fusional event, the low levels of antibody production by the progeny of putative hybrids, and the cessation of antibody production by derived cultures; however, stable human antibody-secreting hybrids now exist. 28,52,88,99,138,139.167 As problems of the availability of sensitized human B cells for fusion, and better human myeloma fusion partners become solved, great progress should occur with human hybridoma.
Monoclonai Antibodies as In Vitro Markers
Immunohistochemistry
With the use of the antigenic characteristics of specific cells to histologically identify them, a high degree of diagnostic specificity can be obtained by immunohistochemistry. With the currently utilized horseradish peroxidase-antihorseradish peroxidase and antigenbinding cell techniques, 16,174 the presence of antigen can be precisely defined at subcellular levels in a sensitive and reproducible manner. Moreover, using monoclonal antibodies as reagents, a new degree of reproducibility and specificity is now possible.
In neuroendocrinology, monoclonal antibodies have been developed against receptor molecules, hormones, growth factors, and differentiation antigens.54'55 '114,125,175 Monoclonal antibodies have been utilized to study hormone action, to characterize the distribution of receptors and hormones within the CNS, and to act as physiological probes. This technology has the ability to define and characterize new molecules and to clarify the complex interactions that occur within the CNS.
The use of monoclonal antibodies has also resulted in a new way of thinking about the origin and interrelationships of CNS components. The initial work in this field is well outlined in the proceedings of a workshop on monoclonal antibodies against neural antigens. 117 Utilizing monoclonal antibodies, several investigators have systematically defined the expression of antigens on the various components of the CNS. 63,64,77'82, 97 With these antigens as markers for mature cell components, subsequent work has been directed toward evaluating antigen expression during normal CNS development and determination of tumor-associated markers. [15] [16] [17] 115, 116, 157, 158, 161, 180, 181, 186, 189, 190 Although these studies are still in the preliminary stage, they are evolving a new perspective on the relationships among normal and neoplastic cellular components within the CNS, and identifying antigenic determinants which may be specific for a given tissue or tumor. 17~ In addition, monoclonal antibodies directed against human leukocyte surface antigens (Leu 1, 2, 3) have allowed characterization of the distribution and pattern of mononuclear cell infiltrates in human gliomas, providing a means for further exploring the tumor-host interaction. 184 The capacity to distinguish between normal organspecific and tumor-specific antigens is of the utmost importance. This ability would provide specific histological diagnosis, determine the cell of origin of many CNS tumors, allow early identification of tumors, possibly identify prognostic factors for the natural course of the disease, and predict the response to various therapeutic modalities. At our current level of understanding, the study of CNS tumor-associated antigens is largely at a descriptive stage, and human neuroectodermal tumor-associated antigens defined by monoclonal antibodies now fall into four broad categories: biochemically defined markers, shared nervous systemlymphoid cell markers, shared neuroectodermal-oncofetal markers, and putative restricted tumor markers. It is hoped that in the future the immunohistochemical techniques using monoclonal antibodies will prove as useful in classifying and identifying CNS tumors as they have been with leukemias. ~~
Biochemically Defined Markers
There are substances which have been biochemically defined and have varying degrees of specificity for the CNS and/or CNS tumors. The majority of these are molecules which were initially identified with polyclonal antibodies and are now being further defined and characterized with monoclonal antibodies. Among these substances, glial fibrillary acidic protein (GFAP) is the best known and characterized; GFAP is an intracellular intermediate filament, which was originally isolated from multiple sclerosis plaques 58 and is expressed specifically by astroglial cells. This molecule is widely used as an antigenic marker for normal astroglial cells and for astroglial-derived tumors, 16'43'44'49'56'57 and is structurally related to, but antigenically distinct from, the other intracellular intermediate filament proteins: the cytokeratins, the neurofilaments, desmin, and vimentin. Binding by GFAP has been demonstrated in virtually all types of glial tumors, including ependymomas, oligodendroglioma-astrocytomas, gliosarcomas, angiogliomas, astroblastomas, and in the more morphologically differentiated areas of glioblastomas, but not in ganglion cells, oligodendroglial cells, or in tumors derived from mesenchymal elements. 15,~6 ' 43-45, 49,57.151 In the past, a frequent problem with anti-GFAP polyclonal antibodies was the question of true GFAP specificity. 16.70 With the development of GFAP-specific monoclonal antibodies, these questions have been generally resolved, and anti-GFAP monoclonal antibodies with a high degree of specificity can now be used both in the diagnosis of neurosurgical tumor biopsies and in experimental neuro-oncology. ~6"18~ The true value of the identification of GFAP in CNS tumors is not yet known, but may prove to derive from its ability to define the degree of differentiation and/or cell of origin of the tumor being studied. TM Among the other intracellular intermediate filament proteins, neurofilaments have proven to be reliable markers for neurons. Neurofilaments are protein triplets with the respective molecular weights of 69,000, 145,000, and 200,000 daltons? 57 Neurofilaments have been demonstrated both on normal neurons and, in increased quantities, in pathological conditions such as amyotrophic lateral sclerosis, postencephalitic parkin-sonism, and Pick's disease, as well as following exposure to toxic substances. With the use of monoclonal antibodies, neurofilaments have been identified in peripheral and CNS tumors, including neuroblastomas, ganglioneuroblastomas, ganglioneuromas, pheochromocytomas, central neuroblastomas, pineoblastomas, the ganglial cell components of gangliogliomas, some poorly differentiated neuroepithelial tumors, and some medulloblastomas. 16,103,149,181 AS with GFAP, the neurofilament-specific monoclonal antibody appears to have value primarily as a differentiation marker, being present on the more differentiated elements in a much higher incidence than in less differentiated areas. 18~
Of the soluble proteins in the CNS, S-100 protein has been the most widely evaluated, v6' 79,148 In the past, the S-100 protein has been reported to have potential as a CNS marker, and the expression of this protein has been used to differentiate schwannomas from other histologically similar tumors of neuronal origin. 16 However, this protein is apparently not restricted to the CNS and is not expressed by all neuroectodermal tissue. 16 Part of the problem with S-100 may be that it, in fact, consists of several antigenically different proteins; a problem that may be resolved by the recent development of a monoclonal antibody to a single antigenic determinant of S-100. 86
Cultured melanoma cells, which embryologically are derived from neural crest tissue, have been used to produce monoclonal antibodies which recognize antigens on some neuroectodermal tumors. The antigens detected by these monoclonal antibodies appear to be primarily gangliosides, and include GD2, GD3, and
These are generally present in developing human fetal brain, but are also seen on other tissue including normal brain, retina, and kidney. 3~ The presence of these gangliosides on normal brain may not result in the same degree of labeling as seen with tumor tissue, possibly because of slight biochemical differences or the frequent intracellular, rather than cell-surface, location of these gangliosides in normal brain cells. 13~
The use of these monoclonal antibodies in the identification of cellular components in CNS tumors has not been evaluated.
Shared Nervous System-Lymphoid Cell Markers
In 1964, using polyclonal antibodies, Reif and Allen 146 first demonstrated the presence of an antigen which was expressed on both murine lymphocytes and brain cells. This antigen, known as Thy-1, and antigens with similar patterns of reactivity, have subsequently been reported by various laboratories in several species with different degrees of specificity. These antigens have been reported on animal and human B and T cells, as well as human brain, glioma, melanoma, endometrial carcinoma, and osteosarcoma tissue and derived cell lines. 13 '186'19~ Peripheral nervous system cells also appear to share to a lesser extent some antigens with lymphoid cells. Helson, et a1.,79 generated a monoclonal antibody, DW-1, against a peripheral neuroectodermal tumor cell line which was present on peripheral neuroectodermal tumors, neuroblastoma cell lines, melanomas, hepatoblastomas, and polymorphonuclear leukocytes, without evidence of CNS expression. 79 The identification of these shared antigens between the nervous system and lymphoid cells raises many intriguing questions concerning the interaction between these two systems in various disease states, including primary intracranial tumors.
Shared Neuroectodermal-Oncofetal Markers
Many of the antigens discussed in the previous section also appear to be shared by human neuroectodermal tumors and oncofetal tissue. This separate category includes those antigens present on human neuroectodermal tumors as well as human fetal tissue, including both CNS and lymphoid tissues. These patterns, in this group perhaps more than any other, demonstrate the high degree of complexity and heterogeneity that is being recognized by monoclonal antibodies. The monoclonal antibodies defining these antigens have generally been derived utilizing melanoma cell lines, glioma cell lines, and human fetal brain for immunization. 2~176 The shared antigen recognition within this group is quite complex, although in preliminary work several general patterns appear to be present. These categories are largely based upon the other types of tissue recognized by a given monoclonal antibody. The majority of monoclonal antibodies that identify a shared neuroectodermai-oncofetal antigen tend to have a restricted reactivity pattern, which includes gliomas, neuroblastomas, and melanomas. 48' 154 An exception to this is the monoclonal antibody derived from immunization with melanoma cell line SK-Mel-28, which reacts against a broad spectrum of tissue antigens in-cluding GD3 ganglioside, ~3~ antigens shared by CNS and lymphoid tissue, 48 and oncofetal antigens. 48~154 This is also unusual because generally there is an absence of cross-reactivity between human neuroectodermal tumor and lymphoid tissues, either fetal or adult, when a melanoma cell line is used for immunization in contrast to immunization with human fetal brain, primitive neuroectodermal tumor cells, or neuroblastoma cells. It is only rarely that an anti-human neuroectodermal tumor-associated antigen monoclonal antibody reacts with sarcomas. Among the few that do, there is also a tendency for reaction with normal kidney, a feature that may be significant in later therapeutic or diagnostic use of these monoclonal antibodies. 13' 17,48,j54,162
Tumor-Restricted Markers
Initially, it was hoped that the high degree of specificity of monoclonal antibodies would allow recognition of markers that were restricted to specific types of tumors. This has generally not occurred. Some monoclonal antibodies have been derived which, as of the time of writing this paper, react with only the tumor type of the immunogen and are operationally specific. 83A68 With animal model systems, there have also been reports of antigens that are apparently specific for certain types of animal-model tumors. Among these is a monoclonal antibody noted on nitrosourea-induced rat glioma cell lines which has not been seen on human or canine gliomas, or on normal rat brain? 71 A similar pattern of response has been recognized by Lee and Hwang, ~~ who identified an antigen which was expressed on virally and chemically induced neurogenic rat tumors but was not seen with extensive analysis of normal rodents or human cells. The molecule, a small soluble peptide (< 1000 daltons in molecular weight), represents the most extensively evaluated specific tumor marker to date. A tentative transformation-associated specificity has been reported by Peng, et al., ~35 with a murine monoclonal antibody raised against the C6 rat glioma cell line which reacted with rat and human glioma cells and rat hepatoma cells. Whether these truly represent tumor or transformation-associated antigens is not yet clear. It is hoped that further evaluation of these types of antigens may uncover greater information about specificity in human tumor systems.
Monoclonal Antibodies as Agents In Vivo
Introduction
Since Ehrlich 53 proposed the use of antibodies to deliver chemotherapeutic agents in 1905, the potential for using antibodies to specifically diagnose, localize, and treat human tumors has been actively pursued. With the methodology developed largely by Pressman, With the development of monoclonal antibodies, it was hoped that many of these limitations could be overcome. At the present time, however, many biological questions concerning the accessibility and in vivo specificity of monoclonal antibodies must be examined. Despite the evolving understanding of the patterns of distribution of antigenic determinants that monoclonal antibody technology has identified, major questions still exist concerning the specificity of monoclonal antibodies for the tumor in vivo, the ability to specifically deliver adequate quantities of monoclonal antibodies to the tumor, and the ability of the monoclonal antibodies to specifically localize within the tumor.
Antigenic Iteterogeneity
Human neuroectodermal tumors show a high level of biological complexity and both phenotypic and genotypic heterogeneity. 6-9'22'25'164 Most notable in this are the malignant gliomas, which appear to be composed of genotypically and/or phenotypically heterogeneous populations of cells that are different within each individual glioma, although many overlapping similarities among gliomas from different individuals are seen. The result is that each glioma appears to be heterogeneous: antigenically, in blood-brain barrier permeability, and in virtually all aspects of their biology. One example of this phenotypic heterogeneity i s the variable expression of antigens. Using a single glioma D-54 MG cell line and eight single-cell derived clones, and a panel of 10 anti-human neuroectodermal tumor monoclonal antibodies, we have been able to demonstrate variable antigenic profiles among each of the clones. ~9 Work from other investigators has also demonstrated that antigen expression can be cell-cycle-or phase-dependent, and that antigenic expression can be temporarily or permanently lost fro m cells. 3~,~94 It is conceivable that not only would ther~ be a high degree of antigenic heterogeneity among an d within tumors, but that this pattern of antigenic expression could change with time. This antigenic heterogeneity theoretically necessitates the use of many differentially reactive monoclonal antibodies in order to identify and characterize adequately a sufficient number of cells in each tumor, whether it be for descriptive, diagnostic, localizing, or therapeutic purposes.
In practice, with various neuroectodermal tumors and metastases to the CNS, panels of anti-intracellular intermediate filament monoclonal antibodies have proven useful for determination of histogenesis.133~42 Even with less specifically defined monoclonal antibodies, Kemshead, eta/., 9~ have reported the ability to differentiate among the small-round-cell tumors of childhood, leukemia, and neuroblastoma in bone marrow aspirates utilizing a 12-member monoclonal antibody panel. In a therapeutic role, LeBien, et al., ~~ used a panel of three monoclonal antibodies to eliminate residual leukemic cells in bone marrow ex vivo prior to autologous transplantation. It is conceivable then that the use of panels of monoclonal antibodies may allow the heterogeneity of these tumors to be used to a diagnostic and therapeutic advantage by individualizing each tumor.
Localization
The localization of monoclonal antibodies in tumors is dependent upon the kinetics of antibody-antigen binding, which is an expression of the degree of antibody affinity, number of antigen-binding sites present, and transport kinetics within the various biological compartments.17,68,1og-~ 11, 192 The degree of localization can also be influenced by antigen shedding and modulation, such as that seen with soluble or secreted antigens like carcinoembryonic antigen. 68,69,1~ 1, 172. 173 Moreover, as was noted in the prior discussion, there is evidence to suggest that the expression of antigen is not a static phenomenon. In our laboratory, we have explored the role of these factors by evaluating, by paired labeled analysis, radioscintigraphy, and autoradiography, the localization of radiolabeled monoclonal antibody 8 IC6 (an immunoglobulin G2b directed against a human glioma extracellular matrix protein) in human glioma cell-line tumors growing subcutaneously and intracranially in athymic mice. 17,18 High levels of specific localization of iodine-125 (125I)-monoclonal antibody 8 1C6 and 13q-controlled monoclonal antibodies were demonstrated in the tumor in both locations. With intravenous administration of antibody, peak levels were obtained within 24 to 48 hours and persisted for 5 to 7 days; radioimaging of the subcutaneous tumors was possible during this time.
Other tumors, including those of neuroectodermal origin, have also been localized in animals using radiolabeled antibodies. 5,17"64.69,8~
This successful animal investigation has prompted attempts to localize or image human tumors in vivo and ex vivo using radiolabeled monoclonal antibodies. 29,159,~6~ Farrands, et al., 6~ were able to image a metastatic colorectal carcinoma in the brain with an 13q-labeled monoclonal antibody. More pertinently, Phillips, et al., 136 were able to image a recurrent glioma using an anti-autologous glioma human monoclonal antibody, although the low levels of localization achieved in this study suggest nonspecific uptake rather than specific binding and localization. Larson, et al., 1~176176 following work in tumor-beating mice and rabbits, imaged a human melanoma in vivo using 13q-labeled monoclonal antibodies with a greater than 80% imaging of lesions larger than 1.5 cm. In this last study, three of the six patients developed anti-mouse immunoglobulin antibodies which resulted in a more rapid clearance of monoclonal antibodies, with reduction in tumor imaging and uptake, but no evidence of clinical toxicity. Similar results have been obtained in other settings following crossspecies use of monoclonal antibodies (Ferrone, et al., unpublished data, 1983 ). To date, no severe medical complications have been reported following exposure
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to murine monoclonal antibodies. It appears, then, that radiolabeled monoclonal antibodies can become localized within tumors. This may have important implications in the early detection of tumors and delineation of tumor versus normal tissue, both of which are crucial with CNS tumors. However, numerous factors must still be evaluated experimentally before this technique can be applied clinically. These factors include identifying the precise distribution for each specific monoclonal antibody utilized, the alterations in distribution with serial delivery, and the optimal route of delivery, which is discussed in more detail in the next section. These early studies have established the ability to use monoclonal antibody imaging in human brain tumors. Work is now being directed toward optimizing this imaging and developing its diagnostic and therapeutic potential.
Delivery Techniques
There are many factors involved in the delivery of monoclonal antibodies to solid tumors: the vascularity of the tumor, the vascular permeability throughout the tumor, and the blood flow and extraceUular fluid dynamics within the tumor? 8 Because brain tumors are within the CNS and normally protected from the systemic circulation by the blood-brain barrier, there are further factors involved in their evaluation. With the progress in the development of monoclonal antibodies that localize in tumors, the importance of optimizing delivery becomes more pertinent. To date, very little is known specifically about the accessibility of antibodies and their drug or radionuclide conjugates to intracranial tumor tissue. While this important issue has frequently been debated, only rarely has it been studied experimentally and most information in this general area is derived from studies dealing with drug delivery. L 1.12,21,23,24,50,62,72
The blood-brain barrier has been known to exist for almost a century as a functional barrier to the passage of compounds from the blood into normal brain. In the normal state, ionic compounds, molecules of large molecular weight, and polar nonelectrolytes do not readily pass from the blood into the brain. The barrier appears to exist anatomically at the tight junctions of cerebral capillary endothelia, ~9,143 but other functional factors may also exist. Within both human gliomas and experimental animal tumors, there seems to be a high degree of heterogeneity in the status of the blood-brain barrier. Experimental work on the etiology of this phenomenon has suggested various reasons, including the uneven distribution of abnormal blood vessels in gliomas, varying degrees in vascular permeability within the tumor, and altered blood flow among these regions. 11, 12, [73] [74] [75] The role of delivery to malignant primary tumors has recently been readdressed in the context of route of administration for chemotherapeutic agents. 2~' 23' 24' 5~ 62,72,104 A specific interest is increasing drug delivery to tumors either by direct intracarotid drug admin-istration or by intracarotid administration following transient disruption of the blood-brain barrier. 23' 77' 89 Although many theoretical advantages can be outlined for these various routes, increased efficacy has yet to be documented in an animal model or in humans. Moreover, because of their large size and structure, the delivery of monoclonal antibodies will need to be addressed separately. In experimental studies in our laboratory on rats, intracarotid delivery with selective ligation and prior temporary disruption of the bloodbrain barrier with hyperosmolar agents has been required to deliver significant levels of radiolabeled monoclonal antibodies to normal brain. 23 With this technique, a five-to sixfold increase in radiolabeled anti-glioma monoclonal antibodies is seen in the ipsilateral cerebral hemisphere when compared to intravenous or intracarotid delivery alone. In contrast, with immunosuppressed rats bearing an intracranially transplanted D-54 glioma cell line, paired labeled experiments using J 251-8 1 C6 and ~3 q-control immunoglobulin of the same class delivered by both the intravenous and intracarotid routes alone, specific tumor localization has occurred with no clear advantage in quantity or quality of localization gained by intracarotid administration (Bullard and Bigner, unpublished data, 1984).
Several factors appear to be involved in the delivery of substances to tumors. The transport of substances from a vascular compartment to either normal brain tissue or tumor is influenced by the permeability coefficient of the capillaries for the substance being evaluated, the capillary surface area available for exchange, the time course and concentration of unbound substance in the plasma, and the blood flow to the tissue. Groothuis, et a[., 75 reported regional measurements of the rate of blood flow and blood-to-tissue transport for five experimental brain tumor models. In all of these, either capillary permeability and/or capillary surface area significantly limited delivery. While there was marked regional variation in the rate of blood-to-tissue transport for all of the tumor models, in none of them was blood flow a consistently limiting factor. Cerebral blood flow in vivo has been evaluated in brain tumors to a limited extent. In most of these studies, the regional variation and blood flow values appear to be similar to those of normal white matter. Lz88 However, the complexity of this area of investigation necessitates much further work, and requires a method to measure the rate of blood-to-tissue transport in vivo before most of these factors can be satisfactorily resolved.
Monoclonal Antibodies as Carriers of Drugs or Radionuclides
Introduction If the problems dealing with antibody localization and delivery can be successfully resolved, many potential uses for monoclonal antibodies should develop diagnostically and therapeutically. A major potential use is as a carrier of radionuclides and drugs for the diagnosis and treatment of brain tumors. For localization, imaging, and therapeutic purposes, 17,23 monoclonal and polyclonal antibodies have been successfully conjugated to a variety of toxins and drugs, including the plant toxins ricin, abrin, and gelonin; the bacterial toxins diphtheria toxin-A and Pseudomonas aeruginosa; drugs such as chlorambucil, methotrexate, daunomycin, and neocarzinostatin; several enzymes; ]7,166 and many radionuclides, including 123I, '25I, and 13q. In addition, monoclonal antibodies have been shown to have direct toxicity through antibody-mediated immunological mechanisms, s2 Previously, the specificity of polyclonal antibodies has been a limiting factor in the use of antibody conjugates, as previously discussed. With the development of monoclonal antibodies, however, single-determinant specificity is now possible. Before widespread clinical use of these modalities can occur, extensive studies are necessary to reevaluate the patterns of distribution and potential toxicities. The data that have been generated so far continue to support the potential value of this therapeutic modality.
Toxins
Human neoplasms transplanted in athymic mice have been successfully treated with the plant toxins abrin and ricin. 17,1~ These two compounds are composed of A and B subunits. The A-chain disrupts cellular protein synthesis following binding of the toxin to the cell surface by the B-chain. Either the whole toxin or the toxic A-chain has been bound successfully by both poly-and monoclonal antibodies, allowing specific delivery to target ceils. 14'144"145 '178'179'195 By binding the antibody to the A-chain rather than using whole toxin alone, increased cell specificity is obtained although decreased toxicity has also been noted. Because of this decreased toxicity, animal experiments have initially shown antibody A-chain conjugates to be effective only against small tumors. 14'96 However, the use of F(ab')z (see Fig. 1 ) may allow this limitation to be overcome because of increased binding efficiency. Gelonin and phytolacca americana toxin are two other plant-derived toxins that may be useful. Both of these plant lectins have the same ribosomal inactivating ability as abrin or ricin, but lack B-chain cell receptor binding sites.
The bacterial toxins, diphtheria and P. aeruginosa, are similar to the plant toxins in having A and B fragments but differ in their site of toxicity by enzymatically inactivating eucaryotic ribosomal elongation factor EF-2.193 The bacterial toxins have two disadvantages: they are more difficult to obtain than the plant toxins, and a significant percentage of the human population has already been actively immunized against diphtheria. Experimental work with poly-or monoclonal antibody-bound diphtheria toxin has, however, shown the conjugate to be successful in inhibiting protein synthesis and growth of human lymphoblastoid cell lines and human colorectal carcinoma cell lines in vitro. 66, 67, 150, 179 
Drug Conjugates
Both poly-and monoclonal antibodies with varying degrees of specificity have been successfully coupled to a wide panel of chemotherapeutic agents, including methotrexate, P-phenylenediamine mustard, chlorambucil, melphalan, triaziquinone, alpha-amanitin, vindesine, neocarzinostatin, adriamycin, and daunomycin. 16,65 The advantage of conjugating a chemotherapeutic agent to a monoclonal antibody would be in the specificity of drug delivery with reduced systemic toxicity and the theoretical potential of maintaining therapeutic levels of drug at the tumor site over prolonged periods of time. Experimental data in several animal model systems and against human tumors have suggested the feasibility of achieving this result by either covalently or noncovalently coupling the chemotherapeutic agents to the antibodies. This has been best demonstrated using a monoclonal antibodyadriamycin conjugate against rat mammary carcinoma cells in vivo. 139 In that study, this conjugate specifically localized in tumor tissue in vivo, resulting in delayed tumor growth and prolonged survival in tumor-bearing rats. Significantly lower doses of monoclonal antibodybound adriamycin could be used than would be required for free adriamycin to achieve equivalent survival results.
Antibody-Mediated Immunological Mechanisms
An alternative approach may be based upon new data generated in the field of experimental virology and tumor immunology. Conflicting data were generated relating to polyclonal antibodies and the value of passive serotherapy in the treatment of malignant tumors. However, recent data on monoclonal antibodies have shown therapeutic value in both animal and human subjects. 32 ' 92' 118' 148 In one report, administration of an immunoglobulin G2~ monoclonal antibody alone demonstrated rapid tumor volume reduction of human breast carcinoma transplanted into athymic mice. 32 Histologically, tumor-cell necrosis without inflammatory cell infiltration was noted. This response was seen only with intact immunoglobulin molecules, suggesting a tumoral response requiring the Fc fragment (see Fig. 1 ). In vitro, this has also been seen in antibodydependent cell-mediated cytotoxic assays where the responsiveness of tumor to complement-mediated cytolysis appears to be dependent upon the level of antigen present on the tumor surface. 3~
Additional evidence for the value of passive serotherapy has been generated in virally-induced animal tumorsY "93 Following retrovirus infection in the mouse, viral antigens, most notably gp7 I, are expressed on the cell surface? 55 Passive serum therapy with anti-gp71 monoclonal antibodies can result in cure of these animals, who normally die within 8 to 12 weeks after infection. In addition to the passive serum response, there also appears to be the active development of host antiviral antibodies which play a major role in the survival of the animal. 84' 155,~5~ From experimental data
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in antibody-dependent cell-mediated cytotoxic assays, it appears that these antibodies arm macrophages to lyse tumor cells in vitro and induce macrophage-tumor cell rosette formation in vivo. 85 Immunoglobulin G2~ immune antibodies are more efficient than other immunoglobulin types in mediating these tumordestructive events. Since monoclonal technology in second-generation studies against characterized tumorassociated antigens may allow selection of immunoglobulin type for those most effective in immunotherapy, such as immunoglobulin G2, or their mediating complement-dependent cytolysis, another advantage of monoclonal antibodies is evident. In an extension of this, nonimmunogenic animal tumors have been successfully superinfected with viruses and successfully treated with passive serotherapy against viral antigens. 85' 94 The pertinence of this to human tumors is not yet known but it has been demonstrated that murine monoclonal antibodies against human cancer-associated antigens have successfully localized in human brain-tumor tissue after transplantation into athymic mice and rats. 16 Moreover, human B-cell lymphoma has been treated in man by anti-idiotypic monoclonal antibodies. 1~8' 127 From these data, it is suggested that passive serotherapy with antitumor monoclonal antibodies could be of value in treating human tumors.
Radionuclides
As has been discussed, radionuclides bound to monoclonal antibodies have been successfully used for the imaging of both experimental and human brain tumors. They offer the advantage of being easily detected and quantified through the use of radioscintigraphic imaging, direct counting of tissue levels, and quantitative autoradiography techniques to study distribution, kinetics, and dosimetry.11'~6'~~ These same advantages exist when radionuclides are to be used therapeutically; in addition, radionuclides can produce their beneficial effects without having to enter the tumor cell and/or interact with specific organelles or biochemical pathways because the effect of the ionizing radiation generally affects an area much larger than the cell diameter. This indiscriminate and continuous effect of ionizing radiation, however, also results in exposure of normal tissue to a degree inversely proportional to the selectivity of the delivery and the ability of the conjugate to localize. To date, studies using both poly-and monoclonal antibodies have demonstrated the ability of radiolabeled antibodies to localize to tumors, allowing imaging and therapy in both human tumor xenografts in athymic mice and in man. 5'16"64'65"68'69'124 '176 These preliminary studies strongly support the potential diagnostic and therapeutic uses of radionuclides conjugated to monoclonal antibodies. In our laboratory, we have approached this problem in a sequential manner by experimentally evaluating localization, imaging, and therapeutic studies in human glioma-bearing athymic mice, immunosuppressed rats, athymic rats, and primates, hoping to establish optimal parameters prior to the use of monoclonal antibodies for protocols of Phase I studies in glioblastoma patients. 6't7'~8'21"23'24 We have been able to characterize eight monoclonal antibodies that define glioma-associated antigens. Isas9 These antibodies are directed against cell surface or extracellular matrix antigens and are highly restricted in their distribution, both in vitro and in normal neoplastic tissues. They have been classified as being operationally specific because of their failure to react with normal brain. Of these, 81C6 identifies a glioma extracellular matrix antigen that is present in the basement membranes of the abnormal capillaries found in human glioblastoma, glioblastoma cell lines, and glioma xenografts in athymic mice and rats) 7'18 The antigen identified is distinct from normal fibronectin, collagen, and proteoglycan. In paired labeled experiments with 125I-labeled 81C6 and control immunoglobulin 13q-labeled myeloma immunoglobulin (which is of the same immunoglobulin G2a type), we have demonstrated specific localization of 81C6 in U-251 MG and D-54 MG glioma xenografts in athymic mice and rats, but not in DU-4475 breast carcinoma xenografts? 7 Based upon these data, successful imaging studies have also been performed with glioma xenografts implanted subcutaneously in athymic mice and intracranially in athymic rats? 7 Immunological analysis of the labeled antibody preparations by gel chromatography and binding assays has demonstrated stable antibody specificity in the structure of the radiolabeled conjugates, both before and after injection, 17 with serum half-life equivalent to that previously reported in the literature for unlabeled immunoglobulins of the same class. 59 We believe that these studies strongly indicate a potential therapeutic use for conventionally radiolabeled monoclonal antibodies.
An alternative approach is the use of radionuclides that are secondarily activated. The best characterized of these is the boron-10 (I~ activation by slow neutrons, which results in a recoil lithium atom and an alpha particle. 3'1~ In the past, I~ slow neutron capture therapy of human brain tumors has been reported, 2 as well as the ability to couple ~~ compounds to antibodies. 78'~22 Such compounds would have the same theoretical advantages that have been postulated for the light-activated hematoporphyrin derivatives, most specifically a high target specificity and local effect. The potential of these compounds also deserves further investigation.
Summary
Monoclonal antibodies are a new biological probe for the evaluation of primary human brain tumors. Since their development, they have virtually revolutionized immunology. Although at an early stage of development, their application to neuroimmunology and neuro-oncology has already resulted in a new awareness of the complex relationships that exist within the CNS. With creative use, their specificity and reproducibility can provide the means to qualitatively and quantitatively define the phenotypic heterogeneity of malignant gliomas.
Preliminary data have suggested the ability to localize and image tumors using radiolabeled monoclonal antibodies. Current work is now focused on the development of these antibodies and resolution of the problems associated with delivery and localization. The potential exists to use monoclonal antibodies alone or as carriers of radionuclides, drugs, or toxins for the treatment of malignant gliomas. Both diagnostically and therapeutically, monoclonal antibodies should prove valuable in the rapidly changing areas of neuroimmunology and neuro-oncology. 
